Study	Reason for exclusion
Bauduer 2001	Aminoglycoside
Bodey 1989	A review
Borja 1999	Correspondence ‐ in response to Winston 1998. Does not add any information
Cometta 1995	Aminoglycoside in both arms
Cometta 1996	A review
Cordonnier 1997	Aminoglycoside in both arms
Cornely 2002	Aminoglycoside in both arms
Deaney 1996b	Meta‐analysis
Erman 2001	Aminoglycoside in both arms
Fanci 1992	Aminoglycosides allowed only in one study arm. This is a preliminary report from a larger multicenter study comparing imipenem/ cilastatin (Tienam) versus ceftazidime. Addition of amikacin empirically was allowed by protocol only in the ceftazidime arm.
Gomez 2001	Aminoglycoside in both arms
Hoepelman 1993	Neutropenic patients were excluded from the study
Kieft 1994	Neutropenic patients were excluded from the study
Kuye 1993	A review summarising phase I and III clinical trials of piperacillin‐tazobactam
Longree 2001	Aminoglycoside in both arms
Malik 2002	Comparison with a historic group (49 pts prospectively received meropenem and compared with a 50 pts who received ceftazidime in the immediate past),
Marra 1998	Double‐blind randomised controlled trial conducted as a formulary feasibility study in Canada. 150 patients prescribed imipenem, with or without other medications, meeting inclusion criteria were randomised to imipenem versus piperacillin‐tazobactam. The prescription was for febrile neutropenia in 30 patients, other patients were not neutropenic. We tried to contact the corresponding author unsuccessfully, to obtain outcome data for the subgroup of febrile neutropenic patients. Lacking these data, we excluded this study.
Moroni 1987	Compares ceftazidime‐amikacin vs ceftazidime‐vanco
Papachristodoulou 96	Compares ceftazidime 6g/d versus ceftazidime 6g/d+amikacin 1g/d
Rolston 1991	Non neutropenic patients
Sanz 2002	Aminoglycoside in both arms
Smyth 2002	Pharmacoeconomic study comparing between piperacillin‐tazobactam and meropenem on the randomized population included in Oppenheim 2000.
Sumitani 2007	pharmacokinetics/pharmacodynamics theory model, without a clinical study
Tanindi 1994	Reference could not be obtain. Unknown whether this comparative study is randomized
Varthalitis 1996	RCT comparing cefepime 2gx2 versus cefepime 2gx3 as empiric monotherapy for neutropenic fever. Doesn't compare cefepime to another drug
Zarostsky 2001	Meta‐analysis of trials assessing cefepime infebrile neutropenia